EMMAC is bringing together the latest science and research into the medical benefits of cannabis with pioneering cultivation, extraction and production to establish itself as the European leader in the production and supply of medical cannabis.
EMMAC is at the forefront of the global medical cannabis industry working with research institutions to deliver clinical data regarding the efficacy of medical cannabis for pain and the potential public health benefits for patients.
EMMAC announces pioneering research collaboration with Imperial College London
The partnership between EMMAC and Imperial College London has been forged to deliver a long-term comprehensive research programme designed to shape the future of the medical cannabis therapeutic industry.
EMMAC’s European Operations
EMMAC has developed unique supply and distribution partnerships across Europe to establish itself not only as a thought leader at the very forefront of research into the medical benefits of cannabis but also a European leader in the production and supply of medical cannabis, hemp and other derivative products.
EMMAC Across Europe
Events & Press Releases
The Cannabinoid Conference 2019 will be held on 31st October - 2nd November 2019 in Berlin, Germany. http://cannabinoidconference.org/home
EMMAC and University of Insubria to present abstract at IACM 10th Conference on Cannabinoid in Medicine
31 October 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, announces that the manuscript, "Immunomodulatory Effect of Cannabidiol: Relevance in Multiple Sclerosis" has been selected for
16 October 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, is pleased to announce that it has raised £15 million via an issue of Convertible Loan
10 September 2019, London. EMMAC, the leading European independent medical cannabis company, is pleased to announce an expansion of its research collaboration with Imperial College London. The new research